Feeding Cancer

Emily BurkeBiotech Basics, Cancer, Clinical Trials, Deoxyribonucleic Acid (DNA), Diabetes, Drug Development, Drug Targets, Mechanism of Action, Term of the Week, The WEEKLY

The Metabolics Of Cancer Tackling cancer requires a multi-pronged strategy. Currently, many of the cancer drugs on the market work by inhibiting the signaling pathways that activate cell division. These pathways are often the root cause of cancer—a mutated gene leads to a dysfunctional signaling protein which tells the cell to divide inappropriately. In these cases, the cancer may be treated by inhibiting the … Read More

The Powered Exoskeleton

Emily BurkeBusiness of Biotech, Medical Device, Orphan Disease, Term of the Week, The WEEKLY

THINKING OUTSIDE OF THE BODY Last WEEKLY’s focus on Duchenne muscular dystrophy got us to thinking, what products are available for those with limited mobility? A new type of medical device called a powered exoskeleton certainly caught our eye. Originally conceived as a tool to aid soldiers in lifting heavy objects, medical device companies are turning to exoskeletons as a way to dramatically improve quality of … Read More

Deciphering DMD

Emily BurkeAntisense, Clinical Trials, Drug Development, Drug Targets, FDA, Genetics, Orphan Disease, Orphan Drugs, Ribonucleic Acid (RNA), Small Molecule Drugs

THE ROOT OF DUCHENNE MUSCULAR DYSTROPHY World Duchenne Awareness Day called attention to Duchenne Muscular Dystrophy (DMD) this past Monday. Affecting one in 3,500 newborn baby boys worldwide, this fatal disease is caused by a mutation in the gene that codes for the dystrophin protein. Easily damaged muscle cells, progressive muscular weakness, and serious medical problems—including significant impairment of the heart and lungs—are the direct results of this … Read More

RNAi Crashes The PCSK9 Party

Emily BurkeBiologics, Business of Biotech, Cardiovascular Disease, Clinical Trials, Drug Approvals, Drug Development, Drug Targets, FDA, Mechanism of Action, Monoclonal Antibodies, Ribonucleic Acid (RNA), The WEEKLY

Newest Hopeful In Cholesterol Lowering Landscape Just weeks after the biotech world celebrated the approvals of two new cholesterol-lowering PCSK9 inhibitors, Regeneron/Sanofi’s Praulent and Amgen’s Repatha, a potential future rival arrived in style. Enter Alnylam (Cambridge, MA), with its RNAi-based experimental drug ALN-PSCsc, which just completed Phase I with positive results. What makes PCSK9 inhibitors so hot, and why are the new cholesterol drugs on the market … Read More